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Background: Transient exposures may influence fertility and early embryonic development. To assess the time of
conception in vivo and conduct concurrent biomonitoring, ovulation must be identified prospectively. We report on
the development and validation of a simple, prospective method, the Peak Day method, to determine likely day of
ovulation based upon daily observations of cervical fluid.
Methods: We recruited 98 women to learn the Peak Day method from a brochure, 26 of whom concurrently used
the method with blinded daily urine hormone monitoring (estrone glucuronide and luteinizing hormone). All
women were instructed to complete an exposure questionnaire immediately upon identifying ovulation. Briefly, the
exposure questionnaire captured time-varying and transient exposures such as medication use, water consumption,
and amount of sleep. We assessed timely completion of the exposure questionnaire, agreement of women’s
estimated day of ovulation (EDO) and the EDO by expert review, and agreement between the EDO by expert
review and by blinded urine monitoring.
Results: Of 147 cycles evaluated, women selected an EDO in 130 (88%) and subsequently completed the
periovulatory exposure questionnaire in 122 (94%) cycles. Of the 26 cycles evaluated with blinded hormonal
monitoring, the Peak Day “best quality” algorithm, based upon cervical fluid, identified ovulation ± 3 days of the
urine monitor in 24 cycles (92%).
Conclusions: With simple written instructions, women can identify an estimated day of ovulation and perform
periovulatory exposure assessment. The Peak Day method is highly cost-effective and could be applied by
researchers to target periconceptional or very early developmental stage exposure assessment.
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BiomonitoringBackground
In recent years, the Barker hypothesis initiated a revolu-
tion in our understanding of human development by pro-
posing that events leading up to birth are associated with
outcomes in adult life [1]. Evidence has accumulated for
the effects of intrauterine environmental exposures on
early development and adult health in both animals and
humans, and now the developmental origins of non-
communicable disease is a dynamic research area [2,3].* Correspondence: christy.porucznik@utah.edu
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reproduction in any medium, provided the orEnvironmental contamination by endocrine disrupting
chemicals or mutagens during the fetal period affects vir-
tually all organ systems in fetal development and through-
out subsequent life [3-5]. The mechanism for such action
may be that environmental exposures affect cellular stress,
hormone regulation, or metabolic pathways leading to epi-
genetic changes in the organism [3]. Results from assisted
reproduction techniques suggest that the environment to
which the embryo is submitted affects genetic expression
in ways that alter the phenotype of the organism through-
out its subsequent development [5,6].ral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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our ability to understand the effects of periconceptional
environmental exposures. Exposures that are transient may
have critical influences on fertility and the sensitive period
of early embryonic development. Therefore, initial moni-
toring of key exposures should occur at or near the time of
conception [7,8]. In order to assess the time of conception
in vivo, the time of ovulation must be identified prospect-
ively. Prospectively determining ovulation dates can iden-
tify precise time intervals between ovulation, conception,
implantation, and subsequent development and would
allow for targeted exposure assessment during the relevant
developmental windows, such as fertilization and implant-
ation [8-10].
A number of candidate biomarkers of ovulation exist,
including hormonal biomarkers, menstrual cycle length,
and symptom biomarkers [11,12]. Home ovulation detec-
tion kits based on urinary luteinizing hormone (LH) are
reliable (ovulation by ultrasound occurring within 3 days
of the urine LH surge in 97% of cycles); however, their
daily use would become costly if used in large, population-
based cohort studies [12-15]. A handheld computerized
device based on urinary estrogen metabolites and LH has
also been shown to be reliable in relation to biologic gold
standards and to be effective in field studies [13,16-19].
However, its use may also be limited by cost consider-
ations (currently up to $200 per monitor and > =$1 per
day for test strips) [14,20].
Another frequently used attribute is cycle length, or
fixed formulas for counting days of ovulation. The major
limitation of this method is that there is wide variability
in the length of the follicular (preovulatory) phase, as
well as substantial variability in the length of the luteal
(postovulatory) phase of the menstrual cycle [21-24].
Further, some common exposures, such as recent oral
contraceptive use, systematically delay ovulation [25,26].
While adjustments can be made in calendar calculations
for the purposes of estimating pregnancy rates, calendar-
based approaches are not precise enough to assess peri-
conceptional exposure. Using a calendar-based approach
for the timing of ovulation will frequently be inaccurate
by a week or more [21,22,24].
An alternative approach for identifying ovulation is the
use of symptom biomarkers. Based on the available evi-
dence, it has been proposed that using symptom bio-
markers for ovulation may prove as accurate and effective
as using hormonal biomarkers, at a much more cost ef-
fective ratio for large population-based studies [14,27].
Basal body temperature (BBT) rises soon after ovulation
and is well correlated with the estimated day of ovulation
(EDO) based on gold standard markers (including follicu-
lar ultrasound and serum hormonal measures), but cannot
prospectively identify when ovulation is imminent [28].
Cervical fluid secretion increases greatly in quantity andchanges in quality in the days preceding ovulation, result-
ing in characteristic changes that women can observe,
changes that are also well correlated with gold standards
for the EDO [28-30]. Because cervical fluid changes are
necessary for sperm survival, they also accurately identify
both the beginning and end of the fecund window (com-
monly called the fertile window), or the days when con-
ception is most likely to occur [31,32].
Women can be taught to monitor cervical fluid and/or
basal body temperature biomarkers for ovulation, and they
can monitor them reliably and interpret them accurately as
has been demonstrated in numerous field studies, includ-
ing international settings [33,34]. However, because previ-
ous work has focused on monitoring for family planning
purposes, it has involved relatively intensive instruction
[35-37] (i.e., four or more personal sessions with an in-
structor), which would limit applicability for epidemiologic
assessment in large populations. We report on the pilot
testing and validation of a basic written brochure (printed
or online) for a streamlined, prospective method to identify
the fecund window and likely day of ovulation based upon
self-observation of changes in cervical fluid, with an option
for additional use of basal body temperature. Our motiv-
ation is to develop a tool for environmental epidemiolo-
gists wishing to link environmental exposure assessment
with the periconceptional period or subsequent develop-
mental windows more precisely than is possible with
calendar-based tools. Such precision may not be relevant
for exposures that are continuous, but the timing of expos-
ure assessment may affect greatly the measured values for
time-varying exposures. For example, we are measuring
bisphenol A, an endocrine disruptor, in daily first morning
urine samples in an ongoing cohort and have found daily




Ninety-eight women, ages 18–44, who were not cur-
rently using hormonal contraception were recruited for
the Peak Day pilot or validation studies during 2009–
2011. Women were not required to be sexually active or
trying to conceive to participate. Women were recruited
through friend referrals, flyers, websites and local com-
munity groups. In addition, based upon data within the
Utah Population Database, letters were mailed to
women identified as married for at least two years who
had not yet experienced a live birth. Women in the pilot
study could live anywhere but women who participated in
the validation sub-study were restricted to the Salt Lake
City, Utah area. The University of Utah Institutional Review
Board and the Utah Resource for Genetic Epidemiologic
Research approved the study and written informed consent
was obtained from all participants prior to enrollment.
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ment questionnaire. In addition to demographic infor-
mation and reproductive history, participants also
recorded their current pregnancy intention (scale 0–10,
0 = trying very hard to avoid pregnancy and 10 = trying
very hard to achieve pregnancy), typical level of physical
activity, smoking status, alcohol consumption, weekly fruit
and vegetable intake, and previous knowledge or use of
fertility awareness-based methods. A follow-up phone call
or email was conducted in attempt to complete pertinent
missing enrollment questionnaire data.
The Peak Day method
In an iterative process involving experts in the fields of
natural family planning and fertility awareness, we have
created a streamlined, simplified approach to fertility
awareness instruction to identify the EDO, called the
Peak Day method. Participants in the Peak Day studies
received three sample fertility charts accompanied by a
three-page brochure (printed or online at http://medi-
cine.utah.edu/dfpm/OCRH/peakday/Brochure.pdf ) that
explained how to observe, record, and interpret charac-
teristics of the cervical fluid in order to identify the
likely day of ovulation. In the brochure, participants
were instructed to make external vulvar observations
for the presence of cervical fluid during routine use of
the bathroom and to record each day that slippery,
stretchy, and/or clear fluid was present. They were in-
formed that their EDO is the last day during a men-
strual cycle when they observed fluid with at least one
of these fertile qualities, i.e., the “last fertile sign” algo-
rithm. In most women, cervical fluid diminishes quickly
following ovulation in response to the increased levels
of progesterone with an accompanying rise (~0.3°F) in
temperature. Thus, the EDO can be determined 1–
2 days after it occurs and the fecund window with the
days leading up to ovulation can be identified prospect-
ively [11,14]. Information about seminal fluid and
arousal fluid, which can mimic cervical fluid and are
critical for pregnancy-avoidance fertility awareness-
based methods, were not included in the participant
brochure given that the Peak Day approach is simplified
and not all participants were sexually active or trying to
conceive.
Instruction about measuring, recording, and interpret-
ing basal body temperature was included in the Peak
Day educational brochure as an optional additional bio-
marker that could be used to confirm the occurrence of
ovulation. Women could return their paper charts to
study staff via mail or enter their daily observations se-
curely online. The study coordinator was available by
phone and email to answer questions and made certain
that all participants understood that Peak Day method
should not be used to avoid pregnancy.Pilot study
Of the 98 women recruited for the Peak Day studies, 67
women enrolled in the pilot study alone, to evaluate the ac-
ceptability and usability of the method (Figure 1). Women
reviewed the educational materials and then recorded their
observations of cervical fluid (and basal body temperature,
if desired) and selected Peak Days for up to six menstrual
cycles or until they became pregnant. We asked the
women to complete a short exposure questionnaire once
she determined her EDO, typically at EDO+ 1 day. The
purpose of this was to demonstrate that women could both
identify their EDO and subsequently perform an exposure
assessment task that recorded exposures that occurred on
the day of ovulation.
Validation sub-study
An additional 31 women enrolled in the validation sub-
study in addition to the pilot, agreeing to daily test their
first morning urine using a blinded research version of the
ClearBlue® Easy Fertility Monitor (CBFM) (Inverness
Medical, Waltham MA, USA). These women also per-
formed daily recording of fertility biomarkers accor-
ding to the Peak Day method, and completed periovulatory
exposure questionnaires for two cycles or until beco-
ming pregnant. The clinical version of the CBFM was
developed to assist women in becoming pregnant by
identifying their fertile window through measurements
of both estrone-3-glucuronide (E3G) and LH in urine.
High fertility indicates urinary E3G (typically between
20 and 30 ng/mL) that correlates with the later follicular
phase estrogen rise [13]. The CBFM continues to regis-
ter a high fertility reading until a threshold of urinary
LH is detected, typically >30 IU/I, indicating peak fertil-
ity [13]. Validation research of the CBFM has found that
the day of ovulation occurs one day after the CBFM
urine LH surge (or the first day that peak fertility is indi-
cated) for the majority of cycles [13]. The research ver-
sion of the CBFM for the Peak Day validation sub-study
was blinded so that participants could not receive infor-
mation regarding their fertility status, but rather, daily
results were stored on a data card, which we down-
loaded at the end of each cycle.
Fertility chart expert review
During the course of the pilot study, we observed a num-
ber of cycles with fertile-type observations in the few days
immediately prior to menses. Since premenstrual fluid can
sometimes mimic fertile-type cervical fluid [38], several
participants incorrectly chose Peak Days according to the
“last fertile sign” algorithm based on these premenstrual
observations. Given that the Peak Day method is stream-
lined and self-taught, it became apparent that the instruc-
tions did not adequately clarify the distinction between
true fertile-quality cervical fluid and premenstrual fluid.
98 enrolled in Peak Day 
31 enrolled in validation 
study (used CBFM) 67 enrolled in pilot study
 
3 lost to follow up or 
non-informative chart, 
excluded from analysis  
2 pregnant at 
enrollment, excluded 
from analysis 
12 completed ≥ 4 cycles 
14 completed greater 
than one but less than 4 
charts 
27 lost to follow up or 
non-informative chart, 
excluded from analysis 
17 completed ≥ 4 cycles 
13 completed greater 
than one but less than 4 
charts 
8 pregnant at 
enrollment, excluded 
from analysis  
58 women, 147 cycles 
analyzed 
Figure 1 Participant flowchart.
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Peak Day to simulate what a woman would have likely
picked had she been given more precise instructions
about choosing between true cervical fluid and premen-
strual fluid.
We decided to test an additional algorithm, one that
might eliminate the need for the distinction between
premenstrual fluid and true cervical fluid because one
is asked to observe the quality of cervical fluid rather
than choosing the last day that fluid is present. The
“best quality” algorithm identifies the last day during a
menstrual cycle when a woman observed the most
number of the three fertile-type cervical fluid charac-
teristics, i.e., slippery, stretchy, and/or clear. A subset
of participants was instructed to use this “best quality”
algorithm for comparison to the “last fertile sign”
algorithm.
For all cycles in the study, two independent, blinded
expert reviewers noted the cycle day the womanidentified as her Peak Day and whether she completed
the exposure questionnaire for her self-identified Peak
Day. Additionally the expert reviewers made their own
assessment of a Peak Day based on the “last fertile sign”
algorithm and on the “best quality” algorithm. Expert
reviewers excluded fertile-type cervical fluid observa-
tions seven days prior to menses (premenstrual fluid)
for both algorithms.
Where the two expert reviewers disagreed, an adjudi-
cating assessment was made by a third expert reviewer.
This adjudicating assessment was needed in 12 (11%) cy-
cles for the “last fertile sign” algorithm and in four (4%)
cycles for the “best quality” algorithm. Both the “last fer-
tile sign” and “best quality” algorithms were evaluated in
order to determine the most valid self-identified bio-
marker of ovulation for peri-ovulational data collection
using Peak Day (test method) as compared to the first
day after the urine LH surge was identified by CBFM
(reference method).
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Descriptive statistics were calculated to summarize partici-
pant demographic and charting characteristics (Table 1),
as well as completion rates for determining EDO and
questionnaire exposure assessments. To assess women’s
ability to learn and correctly use the Peak Day method for
identifying their EDO (pilot study), we calculated percent
agreement between women’s identified “last fertile sign”
EDO (method learned via instructional brochure) and ex-
pert review of “last fertile sign” EDO as well as “best qual-
ity” EDO (method learned by a subset of participants via










Age* 28.1 ± 5.8 29.1 ± 4.5 26.8 ± 7.2
BMI† 23.8 ± 5.5 23.7 ± 4.5 23.9 ± 6.9
<18.5 5 (8.6) 2 (6.3) 3 (11.5)
18.5-24.9 34 (58.6) 20 (62.5) 14 (53.9)
25.0-29.9 6 (10.3) 5 (15.6) 1 (3.8)
≥30 8 (13.8) 4 (12.5) 4 (15.4)
Missing 5 (8.6) 1 (3.1) 4 (15.4)
Physical activity‡ 3.2 ± 1.4 3.1 ± 1.3 3.4 ± 1.5
Age at menarche 12.5 ± 1.5 12.7 ± 1.4 12.4 ± 1.8
Gravidity 0.8 ± 1.2 1.0 ± 1.5 0.4 ± 0.6




50 (86.2) 29 (90.6) 21 (80.8)
Hispanic White 2 (3.5) 1 (3.1) 1 (3.8)
Other/Multiracial£ 1 (1.7) 0 1 (3.8)




27 (46.5) 14 (43.8) 13 (50.0)
Self-employed 4 (6.9) 3 (9.4) 1 (3.8)
Homemaker 15 (25.9) 9 (28.1) 6 (23.1)
Student 6 (10.3) 4 (12.5) 2 (7.7)
Unemployed/other 3 (5.2) 1 (3.1) 2 (7.7)
Missing 3 (5.2) 1 (3.1) 2 (7.7)
Education
High School/GED
or < High School
9 (15.5) 6 (18.7) 3 (11.5)
College graduate 45 (77.6) 24 (75.0) 21 (80.8)
Missing 4 (6.9) 2 (6.3) 2 (7.7)
*Age in years.
†Body Mass Index: weight (kg)/height (m)2.
‡Number of days per week.
£Includes Asian, Black/African American, Pacific Islander, American
Indian/Alaskan Native.EDO (Table 2). We conducted two sensitivity analyses: 1)
we excluded women who had previously used a fertility
awareness-based method to clarify how well women can
learn to identify their EDO exclusively using the Peak Day
method; and 2) we assessed agreement after excluding cy-
cles with basal body temperature recordings to assess how
well women can learn to identify their EDO using cervical
fluid observations alone.
To determine the validity of the two Peak Day algo-
rithms (validation sub-study) compared to urine hormone
monitoring, we calculated percent agreement for EDO
based on expert review of the “last fertile sign” and “best
quality” Peak Day algorithms, and the CBFM for the same
day, and within ≤1, ≤2, and ≤3 days. We additionally
assessed agreement for expert review of the “last fertile
sign” and “best quality” after excluding fertile-type cervical
fluid observations seven days prior to menses.
Results
Of the total consented population, 10 women became
pregnant before beginning to chart and 14 women had one
or more uninformative cycles (n = 30 cycles) due to med-
ical issues (e.g., anovulation or continuous cervical fluid) or
incomplete charts (n = 4 cycles), leaving 58 women con-
tributing a total of 147 cycles for analysis. The study popu-
lation was predominately white, non-Hispanic (86%) and
educated (77% completing college or above) with a mean
age of 28.1 years (standard deviation [SD] =5.8), and Body
Mass Index (BMI) of 23.8 kg/m2 (SD = 5.5) (Table 1).
Forty-one percent of women had previously been pregnant,
36% previously had a live birth, and 87% had previously
used hormonal contraception. A majority of women (72%)
had heard of fertility awareness-based methods, but a mi-
nority (28%) had previously tried one or more fertility
awareness-based methods: ovulation urine test kits (n = 9);
cervical fluid with basal body temperature observation
(n = 8); calendar-based method (n = 3); and cervical fluid
observation alone (n = 2).
Women contributed a mean of 3.2 cycles (SD =1.9 cy-
cles) to the study. Among the 147 cycles, women recorded
cervical fluid observations alone in 61% and both cervical
fluid observations and basal body temperature in 39%.
The estimated date of ovulation (EDO) was marked in
88% of cycles and the Peak Day exposure questionnaire
was completed in 94% of cycles for which an EDO was
marked. The majority (40/58 = 69%) of women wanted to
conceive (i.e., pregnancy intention score on study entry
of ≥5 out of 10) and of those wishing to get pregnant,
most conceived within 4 cycles (31/40 = 78%).
Among all cycles in which an EDO was recorded by
women using the “last fertile sign” algorithm, (n = 110),
participants selected the correct EDO in comparison to
the expert-selected “last fertile sign” algorithm in 76% of
cycles, ± 1 day in 82% of cycles, ± 2 days in 87% of cycles,
Table 2 Agreement between woman-selected estimated date of ovulation and blinded expert review according to the




Woman selected EDO excluding women
who previously used a fertility
awareness-based method
Woman selected EDO excluding
cycles for which basal body
temperature was recorded
Window in relation to EDO as
assessed by expert review using
the “last fertile sign” algorithm1
Cycles n = 110 n = 82 n = 67
Exact day n(%) 84 (76) 64 (78) 52 (78)
± 1 day n(%) 90 (82) 68 (83) 56 (84)
± 2 days n(%) 96 (87) 72 (88) 59 (88)
± 3 days n(%) 102 (93) 76 (93) 61 (91)
Window in relation to EDO as
assessed by expert review
using the “best quality” algorithm2
Cycles n = 20 n = 10 n = 9
Exact day n(%) 18 (90) 8 (80) 7 (78)
± 1 day n(%) 19 (95) 9 (90) 8 (89)
± 2 days n(%) 20 (100) 10 (100) 9 (100)
± 3 days n(%) 20 (100) 10 (100) 9 (100)
Abbreviations: EDO (estimated day of ovulation).
1Last day during a menstrual cycle when a woman observed any of the three fertile-type cervical fluid characteristics.
2Last day during a menstrual cycle when a woman observed the most number of fertile-type cervical fluid characteristics.
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previously used a fertility awareness-based method slightly
improved agreement. Excluding cycles with basal body
temperature observations slightly decreased agreement be-
tween participant-selected EDO and expert selected EDO.
Agreement was higher when participants used the “best
quality” algorithm (n = 20). Participants selected the cor-
rect EDO in comparison to expert-selected exactly in 90%
of cycles, ± 1 day in 95% of cycles, and ± 2 days in 100% of
cycles. When women who had previously used a fertility-
based method were excluded, agreement decreased to 80%
agreement for an exact match and to 90% ± 1 day. There
was no change in agreement for ± 2 and ± 3 days. Agree-
ment on the exact day and ± 1 day dropped slightly more
when cycles with basal body temperature observations
were excluded, but again, remained unchanged for ± 2
and ± 3 days (Table 2).
In the validation sub-study (n = 26), the “last fertile sign”
algorithm as identified by the expert reviewers selected
the same day as the CBFM in 19% of cycles, ± 1 day of the
monitor in 54% of cycles, and ± 2 and ± 3 days of the
monitor in 77% of cycles. In comparison, the “best quality”
algorithm had higher sensitivity: it identified the same day
as the monitor in 19% of cycles, ± 1 day of the monitor in
65% of cycles, ± 2 days of the monitor in 88% of cycles,
and ± 3 days of the monitor in 92% of cycles (Table 3). Ex-
cluding the seven days prior to menses improved agree-
ment for “last fertile sign” algorithm, but made no
difference in agreement with “best quality” algorithm since
the premenstrual cervical fluid was present but did not
have the same degree of fertile characteristics as observed
around ovulation.Discussion
Our findings demonstrate that women are both able to
identify their EDO following self-instruction in fertility bio-
markers (primarily cervical fluid) and willing to complete
an exposure assessment task when they identify their EDO.
Our results suggest that the likely day of ovulation +/− 3
days can be reliably determined using the Peak Day “best
quality” algorithm, with no apparent benefit (or detriment)
from additionally using BBT observations. The “best qual-
ity” had higher sensitivity to detect the EDO compared to
the “last fertile sign” algorithm. The novel contributions of
this study are the viability of streamlined, self-instruction
to identify the EDO, and the higher sensitivity to identify
the timing of ovulation when using the “best quality” algo-
rithm, as compared to our original “last fertile sign” algo-
rithm. For a large, population-based cohort study of
couples trying to conceive, neither in-person instruction
nor daily hormone monitoring are logistically or economic-
ally feasible, and the Peak Day method represents a cost-
efficient alternative for determining ovulation for the pur-
poses of periovulatory/periconceptional exposure assess-
ment. Additionally, researchers could use the Peak Day
EDO information to establish dates for blood draws timed
to developmental windows during pregnancy.
Although some women chose to use BBT as an add-
itional sign in a large proportion of cycles (39%), we did
not find any evidence that use of BBT improved accuracy.
However, we cannot exclude the possibility that women
self-selected somewhat more difficult cycles for BBT use
where BBT influenced the observations and interpretations
to improve accuracy. The slightly increased agreement
when excluding women who have previously used other
Table 3 Sensitivity of peak day method for determining estimated day of ovulation compared to Clearblue® Easy
fertility monitor in 26 cycles
Exact day ≤1 day ≤ 2 days ≤ 3 days >3 days
n (%) n (%) n (%) n (%)
“Last fertile sign1” algorithm including seven days prior to menses 4 (15) 13 (50) 18 (69) 18 (69) 8 (31)
“Last fertile sign1” algorithm excluding seven days prior to menses 5 (19) 14 (54) 20 (77) 20 (77) 6 (23)
“Best quality2” algorithm including seven days prior to menses 5 (19) 17 (65) 23 (88) 24 (92) 2 (8)
“Best quality2” algorithm excluding seven days prior to menses 5 (19) 17 (65) 23 (88) 24 (92) 2 (8)
1Last day during a menstrual cycle when a woman observed any of the three fertile-type cervical fluid characteristics.
2Last day during a menstrual cycle when a woman observed the most number of fertile-type cervical fluid characteristics.
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with previous training may have a more difficult time ex-
clusively using the Peak Day method for identifying EDO
and might benefit from special instruction on how not to
confuse methods.
Several other approaches to observing cervical fluid exist
but none are self-taught without assistance of a trained
teacher of natural family planning or nurse, and teach
women to identify an EDO. One simplified instructional
approach and algorithm for observing cervical fluid (Two-
Day Method) has been developed and validated for family
planning purposes; however, it does not teach women to
identify an estimated day of ovulation [39]. The Creighton
Model Fertility Care System teaches women to observe cer-
vical fluid using the same three characteristics as the Peak
Day method but it requires personal instruction with a
trained teacher over a period of several months [35-37].
The Marquette University Natural Family Planning (NFP)
website [nfp.marquette.edu] allows users to learn about
NFP methods online and chart there with primarily self-
taught methods, but the website is actively managed by
nurses and physicians that interact with participants [40].
Unlike the Creighton Model Fertility Care System and the
Marquette University NFP website, the Peak Day method is
not designed for family planning, nor for medical applica-
tions such as evaluation and management of infertility [38].
A recently published study similarly compared partici-
pant perceived peak days of fertility to CBFM identified
peak days, but without use of cervical mucus monitoring
[41]. In that study, only 56% of women estimated the day of
ovulation within ±2 days of the CBFM identified peak day
[41], much less than the 88% agreement seen with the “best
quality” algorithm when compared to CBFM. This suggests
that cervical mucus monitoring is an accurate and efficient
way for women to prospectively identify ovulation without
need for an external hormone monitoring device.
The Peak Day method identifies a much more precise
window of the periconceptional period than that used in
most previous studies of periconceptional exposures. Prior
studies have used various definitions of the periconcep-
tional period ranging from the month of conception
[42,43], to a 2–3 month window including conception[44-47], to a six month window including conception
[48,49], to the three months prior to and during the preg-
nancy [50,51], and the year before the pregnancy [52]. In
addition, many previous studies of periconceptional expo-
sures and pregnancy outcomes have relied on maternal re-
call of past exposures [42,43,45,48-52]. Such means of
timing exposure assessment may be adequate for expo-
sures that are habitual or easy to recall but would be inef-
fective for exposures that are transient or require analysis
of biospecimens. Further, environmental exposures that
affect probability of conception or time to pregnancy
(TTP) can only be studied in prospective cohorts because
of the bias inherent in recruiting pregnant women into
studies. Application of the Peak Day method in a cohort
would allow for concurrent measurement of exposure via
diaries, biomonitoring, or short-term recall.
Retrospective exposure measurement hampers our ability
to understand the effects of periconceptional environmental
exposures. The Peak Day method could be applied in pro-
spective studies of fecundability to address these limitations.
We are presently using Peak Day (“best quality” algorithm)
to time biospecimen collection and questionnaire-based ex-
posure assessment for bisphenol-A (BPA) in a prospective
cohort of couples trying to conceive. Because of the import-
ance of the male partner in explaining TTP variation, we
are using the Peak Day method to assess both the female
and male periconceptional exposure to BPA [53]. It is im-
portant to emphasize, however, that the Peak Day method
could be applied in the context of targeting exposure as-
sessment for any time-varying exposure.
A minority of women in this study had prior experience
with self-observation of fertility signs, but there was good
acceptance of the method as indicated by completion of
the protocol. We are using the same method in our
current preconception cohort, and it is well-accepted by
this population trying to conceive. We are unable to
speculate how acceptable the method would be to a gen-
eral population of women.
Further studies are needed to assess how well the Peak
Day method can be learned and used by less educated
women. Previous studies have shown that women of low
educational status can learn and reliably use other cervical-
Porucznik et al. BMC Women's Health 2014, 14:4 Page 8 of 9
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[39,54] so we are optimistic for the potential of the Peak
Day method in such populations, possibly with some
adaptation. We had a limited number of cycles to assess
validity of the Peak Day algorithms compared to the
CBFM, and a limited number to assess whether concur-
rent basal body temperature observations or previous
use of other fertility-awareness based methods affect
validity. Further research should confirm that women
can apply the “best quality” algorithm to identify their
EDO directly and more systematically address the im-
pact of additionally recording their BBT (e.g., possibly
by a randomized assignment to additionally using BBT).
Finally, while the Peak Day method is appropriate for
women of normal fertility, it is not appropriate for
women with some menstrual cycle disorders, including
oligomenorrhea or continuous cervical fluid.
Conclusions
In summary, the Peak Day method is a novel and simple
method for timing assessments for exposures relevant
to fertility, pregnancy, and perinatal outcomes that
would be difficult or impossible to assess retrospectively
with precision. In 92% of cycles in this pilot study, the
likely day of ovulation ± 3 days was reliably determined
using the Peak Day “best quality” algorithm. Women
completed the exposure questionnaire as instructed in
94% of cycles for which an EDO was identified. The
Peak Day method is promising for studies of environmen-
tal exposures in very early pregnancy, where prospective
determination of ovulation/conception is essential and the
large population required to detect small effects may make
daily urine hormone monitoring cost-prohibitive.
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